Gout Market Research Report – Forecast to 2030

Gout Market Research Report: By Type (Tophaceous Gout and Pseudogout), By Treatment (Medication, Self-Care), By Diagnosis (Ct Scan, Ultrasound, Urine Test, Blood Test), And By End-User (Hospitals, Specialty Centers, Homecare) – Global Forecast Till 2030

ID: MRFR/Pharma/4453-HCR | | Region: Global | 100 Pages         

Gout Market Speak to Analyst Request a Free Sample

Gout Market Overview


The gout market is anticipated to reach USD 4162.5 Million by 2030 at 11.75% CAGR during the forecast period 2022-2030. A gout is a painful form of arthritis caused by the accumulation of uric acid crystals in the joints. Men are more commonly affected than women. Gout is caused by elevated uric acid levels in the blood. Certain health conditions, such as high cholesterol, high blood pressure, and drugs that promote high uric acid levels, are all major risk factors for gout. Gout can also be caused by factors such as a red meat-rich diet, obesity, and excessive alcohol intake.


Around 3 million Americans suffer from gout, which is growing increasingly widespread as a result of our sedentary lifestyle. Because the symptoms are similar to those of other illnesses, the condition is frequently misdiagnosed or disregarded. The rising prevalence of obesity, rising senior population leading to an increase in patient population, expanding cigarette smoking population, growing mass youthful population predisposed to a sedentary lifestyle, and rising desire for sophisticated treatment are all driving the worldwide gout market.


Figure:  Gout Market, by Region, 2016 (%)


 Gout Market, by Region


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation and market research future analysis


Intended Audience



  • Pharmaceutical Manufacturers and Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Segments 


The gout market is segmented on the basis of treatment, type, end-user, and diagnosis. 


On the basis of type, the market is segmented into tophaceous gout and pseudogout.


On the basis of treatment, the market is segmented into medications and self-care. The medication segment is further sub-segmented into Allopurinol, Febuxostat, Probenecid, Indomethacin, Diclofenac, and Ibuprofen.


On the basis of diagnosis, the market is segmented into X-ray, CT scan, blood test, MRI, ultrasound, urine test, and others.


On the basis of end-user, the market is segmented into hospitals, specialty centers, and homecare.


Research Methodology


 Gout Market,Methodology


Source: World Health Organization, Centers for Disease Control and Prevention, Expert Interview, Annual Report, White Paper, Company Presentation, and Market Research Future Analysis


Regional Analysis


The North American gout market is a growing market. On a regional basis, the Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. The increasing number of passive smokers, along with the increasing older population is likely to drive the market. Additionally, the growing healthcare expenditure and increasing demand for technologically advanced treatments and products along with the increasing government support are likely to enhance the growth of the gout market in North America. Additionally, according to a survey conducted by the National Centre for Health Statistics, in the year 2014, around 70% of adults were considered to be obese in the U.S.


Europe is the second largest market and holds a healthy share in the gout market. The European market is expected to register a healthy CAGR during the forecast period owing to the availability of newer and advanced treatment facilities and increasing skilled medical professionals along with growing need for better healthcare infrastructure. Furthermore, increasing older population, along with the growing inclination towards sedentary lifestyle are driving the growth of the gout market. For instance, Eurostat estimated that over 19.2% of the population in Europe was aged 65 and above. This increasing older population is likely to drive the growth of the gout market.


Asia Pacific is expected to be the fastest growing market due to increasing prevalence of chronic gout. China is the fastest growing region owing to an increasingly older population. The increasing awareness about the health and availability of new treatment methods drives the market in this region. The increasing healthcare expenditure and improvement in the standard of living are driving the growth of the gout market in the Asia Pacific region.


The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market owing to the development of the healthcare industry and increasing availability of specialty care centers.Recent Development

Aurobindo Pharma Limited, a multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, recently announced that the US Food and Drug Administration (USFDA) has given the company clearance to manufacture and commercialize Bortezomib for Injection, 3.5 mg. Bortezomib is an anti-cancer drug that helps people with multiple myeloma and mantle cell lymphoma.


The US Food and Drug Administration (FDA) recently granted priority consideration of Horizon Therapeutics plc's supplemental Biologics License Application (sBLA) to broaden the label for KRYSTEXXA with methotrexate, an immunomodulator routinely given by rheumatologists. KRYSTEXXA is used to treat persistent gout in adults who have failed to respond to other treatments, often known as uncontrolled gout. KRYSTEXXA, the first and only biologic medication licensed for uncontrolled gout, has revolutionized the course of treatment for persons with uncontrolled gout by significantly decreasing the disease's physical impact.


Key Players  


Some of the key players in the gout market are Takeda Pharmaceutical Company Ltd., Savient Pharmaceuticals, AstraZeneca plc, Merck& Co. Inc., Inc.Ardelyx, Inc., Astellas Pharma Inc., and Novartis AG.



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Gout Market CAGR would be 11.75% during the forecast period.

Diagnosis segments in Gout Market report are CT scan, X-ray, MRI, ultrasound, blood test, urine test, and others.

End users mentioned in Gout Market report are specialty centers, hospitals, and homecare.

North America would lead Gout Market growth.

The Asia Pacific market would register the fastest Gout Market growth.